| 1.24 0.06 (5.08%) | 11-11 15:44 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.56 | 1-year : | 1.78 |
| Resists | First : | 1.34 | Second : | 1.52 |
| Pivot price | 1.18  |
|||
| Supports | First : | 1.03 | Second : | 0.86 |
| MAs | MA(5) : | 1.15 |
MA(20) : | 1.2 |
| MA(100) : | 1.2 |
MA(250) : | 1.53 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 57.4 |
D(3) : | 37.4 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 3.77 | Low : | 0.86 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALLO ] has closed below upper band by 26.9%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.23 - 1.24 | 1.24 - 1.24 |
| Low: | 1.15 - 1.16 | 1.16 - 1.16 |
| Close: | 1.17 - 1.18 | 1.18 - 1.19 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Mon, 10 Nov 2025
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Mon, 10 Nov 2025
Allogene (NASDAQ: ALLO) to join 3 conferences: TD Cowen, Jefferies London, Piper Sandler - Stock Titan
Sat, 08 Nov 2025
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2025 Earnings Call Transcript - Insider Monkey
Fri, 07 Nov 2025
Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T (ALLO) - Seeking Alpha
Fri, 07 Nov 2025
Allogene Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView
Fri, 07 Nov 2025
Allogene Therapeutics: Q3 Earnings Snapshot - ctinsider.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 222 (M) |
| Shares Float | 165 (M) |
| Held by Insiders | 17.4 (%) |
| Held by Institutions | 73.9 (%) |
| Shares Short | 19,490 (K) |
| Shares Short P.Month | 20,290 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27 % |
| Return on Equity (ttm) | -55.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.82 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -173 (M) |
| Levered Free Cash Flow | -95 (M) |
| PE Ratio | -1.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|